PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments
(firmenpresse) - Integrated offering to be provided by new dedicated service group under PAREXEL® Access
BOSTON, September 6, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a new end-to-end service offering to provide real-world data insights that help life science companies more effectively demonstrate product value.
“In an increasingly competitive market, leveraging data to demonstrate value is critical. However, unstructured data can make it difficult to overcome gaps in real-world evidence,” said Joshua Schultz, Senior Vice President and Worldwide Head of PAREXEL Access. “Our new service will allow clients to more seamlessly collect and communicate the specific data that payers, physicians, and patients require to establish that a new product offers greater benefits than the existing standard of care.”
PAREXEL’s new offering delivers fit-for-purpose real-world data strategies designed to accelerate market access and mitigate commercial risk. By addressing key factors necessary to demonstrate a product’s value during late-stage development, as well as before and after launch, the offering enables clients to provide high quality evidence that highlights a drug’s unique value.
To deliver this service, PAREXEL has developed a new dedicated real-world data service team with expertise in epidemiology, health economics and outcomes research, market access, analytics, medical sciences, and safety. The group is an expansion of the PAREXEL® Access unit, which provides a complete and simplified solution encompassing evidence-based services throughout the product lifecycle.
The new offering is the latest addition to PAREXEL’s Connected Journey™ of more than 40 data-driven services. The service’s advanced data-aggregation capabilities help assure that clients have access to critical intelligence to inform and support value demonstration. Through these capabilities, primary and secondary data are combined from multiple sources, such as healthcare providers, patient reported outcomes, and electronic data capture, and are leveraged for optimal execution of late-stage programs.
PAREXEL’s real-world data service offering is available worldwide. For more details, please visit: https://www.parexel.com/solutions/access/real-world-evidence/real-world-data-services.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 52 countries around the world, and had approximately 18,900 employees at the end of the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL Contacts:
Media:
Dana Robie
Tel.: +1 781-434-4772
Email: Dana.Robie(at)PAREXEL.com
Jenny Radloff, PAN Communications
Tel.: +1 617-502-4300
Email: PAREXEL(at)pancomm.com
Investors:
Ronald Aldridge
Tel.: +1 781-434-4753
Email: Ron.Aldridge(at)PAREXEL.com
Datum: 06.09.2017 - 15:53 Uhr
Sprache: Deutsch
News-ID 558929
Anzahl Zeichen: 2473
contact information:
Contact person: RealWire
Town:
Lincoln
Phone: +44 (0)1522 883 640
Kategorie:
Pharmaceuticals & Biotech
Typ of Press Release: bitte
type of sending: Veröffentlichung
Diese Pressemitteilung wurde bisher 487 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments"
steht unter der journalistisch-redaktionellen Verantwortung von
RealWire (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
